EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Comparison of the efficacy of enfortumab vedotin between patients with metastatic urothelial carcinoma who were treated with avelumab or pembrolizumab: real-world data from a multi-institutional study in Japan

Yosuke Hirasawa, Takahiro Adachi, Takeshi Hashimoto, Wataru Fukuokaya, Yuhei Koike, Yuji Yata, Kazumasa Komura, Taizo Uchimoto, Takuya Tsujino, Kazuki Nishimura, Kiyoshi Takahara, Masanobu Saruta und 7 weitere

Journal of Cancer Research and Clinical Oncology · 2024

DOI: 10.1007/s00432-024-05717-2 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Cancer Research and Clinical Oncology, 2024. Verfasst von Yosuke Hirasawa und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Tokyo Medical University, 6-7-1, Nishi-shinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan. Hauptthemen laut MEDLINE: Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science: JSPS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Enfortumab vedotin (EV) is a novel antibody–drug conjugate approved for metastatic urothelial carcinoma (UC) refractory to prior treatment with immune checkpoint inhibitors (ICIs). However, the difference in efficacy of EV after each ICIs and prognostic factors are not well known. We aimed to compare the efficacy of EV in patients with metastatic UC who were treated with avelumab or pembrolizumab and to identify the prognostic factors.

Methods

The records of 100 patients with advanced metastatic UC who received EV after the administration of either avelumab or pembrolizumab were retrospectively collected from five academic hospitals in Japan.

Results

The median follow-up period was 6.7 months. The median overall survival (OS) and progression-free survival (PFS) in the EV after avelumab/pembrolizumab group were not reached/14.7 months (p = 0.17) and 10.4/5.2 months (p = 0.039), respectively. The objective response rates (ORR) were 66.6% and 46.8% in EV after avelumab and EV after pembrolizumab groups, respectively (p = 0.14). Multivariate analysis identified histological variants, liver metastasis, low serum albumin levels, and high serum CRP level as significant poor prognostic factors. The median OS and PFS of cachexia patients with both low serum albumin levels and high serum CRP levels were 6.0 months and 0.93 months, respectively.

Conclusion

PFS was superior in patients treated with EV after avelumab to EV after pembrolizumab. However, OS showed no significant difference between the two groups. Because the prognosis of patients with cachexia is extremely poor, the initiation of EV should be discussed in these patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Transitional CellUrinary Bladder NeoplasmsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedHumansCachexiaJapanRetrospective StudiesSerum Albumin

Stichwörter der Autor:innen

AvelumabBladder cancerEnfortumab vedotinPembrolizumabUrothelial carcinoma

Substanzen

pembrolizumabenfortumab vedotinavelumabSerum AlbuminAntibodies, MonoclonalAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Urology, Tokyo Medical University, 6-7-1, Nishi-shinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan.
  • Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.
  • Department of Urology, Osaka Medical and Pharmaceutical University, Osaka, Japan.
  • Department of Urology, Fujita-Health University School of Medicine, Aichi, Japan.
  • Department of Urology, Faculty of Medicine, Kindai University, Osaka, Japan.
  • Department of Urology, Tokyo Medical University, 6-7-1, Nishi-shinjuku, Shinjuku-ku, Tokyo, 160-0023, Japan. yondk2005@gmail.com.

Förderung

  • Japan Society for the Promotion of Science: JSPS

Zitieren

APA

Hirasawa, Y., Adachi, T., Hashimoto, T., Fukuokaya, W., Koike, Y., Yata, Y., Komura, K., Uchimoto, T., Tsujino, T., Nishimura, K., Takahara, K., Saruta, M., Fujita, K., Hashimoto, M., Uemura, H., Shiroki, R., Azuma, T., Kimura, T., & Ohno, Y. (2024). Comparison of the efficacy of enfortumab vedotin between patients with metastatic urothelial carcinoma who were treated with avelumab or pembrolizumab: real-world data from a multi-institutional study in Japan. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-024-05717-2

Vancouver

Hirasawa Y, Adachi T, Hashimoto T, Fukuokaya W, Koike Y, Yata Y, et al. Comparison of the efficacy of enfortumab vedotin between patients with metastatic urothelial carcinoma who were treated with avelumab or pembrolizumab: real-world data from a multi-institutional study in Japan. Journal of Cancer Research and Clinical Oncology. 2024. doi:10.1007/s00432-024-05717-2

BibTeX
@article{Hirasawa2024,
  author = {Hirasawa, Yosuke and Adachi, Takahiro and Hashimoto, Takeshi and Fukuokaya, Wataru and Koike, Yuhei and Yata, Yuji and Komura, Kazumasa and Uchimoto, Taizo and Tsujino, Takuya and Nishimura, Kazuki and Takahara, Kiyoshi and Saruta, Masanobu and Fujita, Kazutoshi and Hashimoto, Mamoru and Uemura, Hirotsugu and Shiroki, Ryoichi and Azuma, Takashi and Kimura, Takahiro and Ohno, Yoshio},
  title = {Comparison of the efficacy of enfortumab vedotin between patients with metastatic urothelial carcinoma who were treated with avelumab or pembrolizumab: real-world data from a multi-institutional study in Japan},
  journal = {Journal of Cancer Research and Clinical Oncology},
  year = {2024},
  doi = {10.1007/s00432-024-05717-2}
}
Kostenlos starten →